MetaCap

Elutia (ELUT) vs eXoZymes (EXOZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Elutia (ELUT) has outperformed eXoZymes (EXOZ) over the past year, gaining 52.6% versus a loss of 81.8%. Elutia is the larger company by market cap ($40.0 million vs $27.4 million), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELUT+52.56%EXOZ-81.84%
+116%+12%-91%
Nov 21, 20251 yearNov 20, 2026
ELUT-74.72%EXOZ-73.88%
+89%-2%-93%
Nov 11, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELUT versus EXOZ key metrics
MetricELUTEXOZ
Share price$0.9001$2.91
Market cap$39.96M$27.42M
1-day change+11.12%-14.05%
YTD return+29.88%-73.35%
1-year return+52.56%-81.84%
5-year return-82.76%—
EPS (TTM)$-0.68$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$12.29M—
Revenue growth (YoY)-15.03%—
Net income (latest FY)$53.38M$-9.16M
Gross margin53.66%—
Operating margin-218.91%—
Net margin434.23%—
52-week high$1.39$16.16
52-week low$0.50$2.81
Distance from 52-week high-35.01%-82.02%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+455.49%—
Average volume185.17K10.14K
Shares outstanding44.40M9.44M
Employees2532
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELUT has outperformed EXOZ by 134.4 percentage points over the past year.

About Elutia

ELUT stock →

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees

About eXoZymes

EXOZ stock →

eXoZymes, Inc. operates as a development stage biotechnology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 32 employees

ELUT vs EXOZ FAQ

Which is bigger, Elutia or eXoZymes?

Elutia (ELUT) is larger, with a market capitalization of $39.96M compared with $27.42M for eXoZymes (EXOZ).

Which stock has performed better over the past year, ELUT or EXOZ?

ELUT returned +52.56% over the past 12 months, compared with -81.84% for EXOZ (price return, excluding dividends). Past performance does not predict future results.

Are Elutia and eXoZymes in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons